Sunday, January 25, 2015 8:33:27 AM
I don't know who your friend Zincfinger is but I understand his or her point- which is the opposing argument to not go forward with E2. There are clearly 2 sides and yes, there is some risk and some strain on resources, but all of these have been taken into consideration and a decision has been made. There is no turning back at this point, so I guess we have to buckle up and take the ride or not. Your choice.
Now, moving forward, the next bottlenecks are manpower and getting all facilities up and working at maximum potential. One officer of the company stated to me that people have been putting in something like 70 hours a week, across the board. They have just hired some more Ph.Ds and are trying to recruit still more, but the supply is limited. There is no question that as Flucide is shown to work and production moves forward, the need for an even larger facility and more people will become the issue. That is why Dr Bordniuk is talking about building an expansive plant with a training facility or working arrangement with an established university.
The NNVC pipeline has to have a faucet on it because they can't do everything at once. So the 'too many pots' point is true- they can't take an all-at-once approach- projects are going to have to get into a queue and the order that projects take will depend on shifting world and market conditions and all kinds of factors. That seems to be evident. Ebola jumped to the front of the line for a lot of reasons, not the least of which was humanitarian, but also included the potential impact for putting the platform into orbit and generating income.
There are going to be problems, but having such a rich pipeline is a problem a lot of companies would love to have. In the meantime, money is not the biggest challenge- they are well funded for now.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM